Greenwich LifeSciences, Inc. (GLSI)
| Market Cap | 462.79M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| Shares Out | 8.79M |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 25 |
| Last Price | $36.16 |
| Previous Close | $36.50 |
| Change ($) | -0.34 |
| Change (%) | -0.93% |
| Day's Open | 36.41 |
| Day's Range | 35.00 - 36.56 |
| Day's Volume | 151,795 |
| 52-Week Range | 3.47 - 72.22 |
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Present at B. Riley Securities and BIO CEO & Investor Conferences
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Participate in Multiple Virtual Investor Conferences During 2021 JP Morgan Healthcare Week
New York, New York--(Newsfile Corp. - January 5, 2021) - Levi & Korsinsky announces it has commenced an investigation of Greenwich LifeSciences, Inc. (NASDAQ: GLSI) concerning possible breache...
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences' LD Micro Presentation Replay Now Available
Breast cancer is the second leading cause of death of women in the U.S. alone. Given the prevalence of the disease, it's no surprise that numerous pharmaceutical and biotech companies are sear...
A lot of buzz-generating IPOs have more than tripled in 2020, but you probably don't know the top U.S. debutante that has soared 583% this year.
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Ring Nasdaq Opening Bell on December 28
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences, Inc. Announces Closing of Public Offering of Common Stock
The company announced the pricing of a public offering of common stock.
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences, Inc. Prices $26.4 Million Upsized Public Offering of Common Stock
New York, New York--(Newsfile Corp. - December 16, 2020) - Levi & Korsinsky announces it has commenced an investigation of Greenwich LifeSciences, Inc. (NASDAQ: GLSI) concerning possible breac...
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Announces Option Agreement for Pre-clinical Coronavirus Vaccine Candidates
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Announces Poster Presentation on Its GP2 Phase III Clinical Trial Design for Recurring Breast Cancer
Immutep (NASDAQ: IMMP) shares are trading higher on Thursday after the company reported a statistically significant survival benefit for key patient groups in its ongoing Phase IIb AIPAC study...
Greenwich LifeSciences made investors rich overnight. Is there any growth left in this breast cancer treatment developer?
Greenwich LifeSciences (NASDAQ: GLSI) is currently up 62.87% to a price of $84.29. The stock's volume is currently 2.41 million, which is roughly 375.86% of its recent 30-day volume average of...
You don't have to be a pandemic fighter to have a big victory for investors.
The stock price of Greenwich Lifesciences Inc (NASDAQ: GLSI) increased 857.74% as it went from $5.20 at the previous close to $49.79 (3:42 PM ET) today. This is why it happened.
Greenwich LifeSciences (NASDAQ: GLSI) shares spiked 1,900% higher Wednesday after the company shared the poster for the GP2 Phase 2b clinical trial final efficacy analysis that was presented W...
Investors had a field day with Greenwich LifeSciences on Wednesday after the tiny biotech company skyrocketed as much as 2,941% on encouraging phase 2b data for its breast cancer immunotherapy...
GLSI stock is soaring Wednesday after Greenwich LifeSciences shared promising results from its breast cancer immunothrapy. The post GLSI Stock: Why Greenwich LifeSciences Is Up 2,000% Today ap...
Shares of Greenwich LifeSciences Inc. were launched to a more than fourfold gain in very active midday trading Wednesday, after the Texas-based biopharmaceutical company displayed upbeat resul...
Greenwich LifeSciences's (NASDAQ: GLSI) stock has been rising Wednesday, up 350.11% to a price of $19.85. Wednesday the stock has been traded at a volume of 2.32 million, about 10387.18% of it...
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Announces Poster Presentation of Five Year Data for GP2 Phase IIb Clinical Trial, Showing 0% Recurrence of Breast Cancer
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Announces New Manufacturing Agreement for its Planned Phase III Clinical Trial and Enters into Lease for Office and Lab Space
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences to Present at the Annual LD Micro Main Event
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Announces Second Publication and Poster Presentation of Phase III Clinical Trial of Breakthrough for Recurring Breast Cancer
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences Announces Publication of Positive Phase IIb Clinical Trial Data for GP2 for the Prevention of Recurring Breast Cancer
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences, Inc. Announces Partnership with Baylor College of Medicine for its Planned Phase III Clinical Trial
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences, Inc. to Participate at Texas Life Sciences Forum Investor Conference
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences, Inc. Announces Acceptance of Two Abstracts at Upcoming Major Breast Cancer Conference
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences, Inc. Announces Completion of Manufacturing of Drug for its Planned Phase III Clinical Trial
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences, Inc. Announces Closing of Initial Public Offering
U.S. IPO Weekly Recap: Health And Tech Dominate The Calendar In An 11 IPO Week
STAFFORD, Texas--(BUSINESS WIRE)--Greenwich LifeSciences, Inc. (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast...
About GLSI
Greenwich LifeSciences, a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other human epidermal growth factor receptor 2/neu-expressing (HER2/neu) cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent recurrence of breast cancer following surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was founded in... [Read more...]
| Industry Biotechnology | IPO Date Sep 25, 2020 |
| CEO Snehal S. Patel | Employees 3 |
| Stock Exchange NASDAQ | Ticker Symbol GLSI |